Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy. NCCP National SACT Regimen. HSE.
Regulatory approval published by the Health Service Executive.
Citation
Pembrolizumab, PACLitaxel 175mg/m2 and CARBOplatin AUC 5 Therapy, 2023, version number 1, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/gynaecology/817-pembrolizumab-paclitaxel-carboplatin-auc-5-therapy.pdfRegulatory approvals
Approved indications from this document for cancer drugs containing at least one biomarker.
| Indication | Statements |
|---|---|
| Treatment of persistent, recurrent, or metastatic cervical cancer in adults whose tumours express PD-L1 with a CPS >= 1. | 1 |
Therapeutic response
Precision oncology relationships for therapeutic response derived from this document.| Type | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| Sensitivity (+) | PD-L1 (CPS) >= 1 | Cervical Adenocarcinoma | Carboplatin, Paclitaxel, Pembrolizumab |